GHRS
GH Research PLC
NasdaqGMUSDEQUITY
DELAYED
Last price
28.33
▼ 0.35 (1.22%)
MARKET · —
Price
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
28.66
Prev close
28.68
Day high
29.15
Day low
28.05
Volume
139.23K
Market cap
—
P/E (TTM)
—
52W range
11.83 – 31.44
Trailing performance
Returnvs SPY
1W
-3.93%
-2.6%
1M
+2.53%
-1.2%
3M
+30.13%
+27.0%
6M
+81.66%
+70.6%
YTD
+123.07%
+110.8%
1Y
+121.67%
+101.7%
3Y
+157.78%
+83.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Free account
3 more panels on GHRS open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Fundamentals
Market cap—
Enterprise value—
Revenue (TTM)—
Gross profit—
EBITDA—
Net income—
EPS (TTM)—
Free cash flow—
Total cash—
Total debt—
Book value / share—
Shares outstanding—
Float—
Short % of float—
Dividend yield—
Beta (5Y)—
Valuation & profitability ratios
Trailing P/E—
Forward P/E—
PEG ratio—
Price / sales—
Price / book—
EV / revenue—
EV / EBITDA—
Gross margin—
Operating margin—
Profit margin—
Return on equity—
Return on assets—
Debt / equity—
Current ratio—
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $38.77M | $35.02M | $29.82M | $20.48M | +10.7% |
| Selling, general & admin | $21.65M | $15.00M | $11.12M | $10.06M | +44.3% |
| Total operating expense | $60.68M | $50.25M | $41.22M | $30.68M | +20.8% |
| Operating income | -$60.68M | -$50.25M | -$41.22M | -$30.68M | -20.8% |
| Net interest income | $4.62M | $5.56M | $5.30M | $735.00K | -16.9% |
| Pre-tax income | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -23.9% |
| Tax provision | $0 | $0 | $0 | $0 | — |
| Net income | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -23.9% |
| Net income to common | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -23.9% |
| Basic EPS | -0.79 | -0.75 | -0.68 | -0.43 | -5.3% |
| Diluted EPS | -0.79 | -0.75 | -0.68 | -0.43 | -5.3% |
| EBIT | -$48.22M | -$38.91M | -$35.52M | -$22.46M | -23.9% |
| EBITDA | -$47.89M | -$38.60M | -$35.21M | -$22.41M | -24.1% |
| Basic shares | 61.04M | 51.95M | 52.33M | 52.02M | +17.5% |
| Diluted shares | 61.04M | 51.95M | 52.33M | 52.02M | +17.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $246.25M | $100.79M | $78.42M | $165.96M | +144.3% |
| Cash & short-term investments | $280.71M | $149.32M | $161.56M | $165.96M | +88.0% |
| Total current assets | $285.98M | $154.22M | $164.09M | $168.54M | +85.4% |
| Property, plant & equipment | $620.00K | $748.00K | $1.07M | $97.00K | -17.1% |
| Total assets | $288.23M | $188.27M | $226.30M | $254.36M | +53.1% |
| Total current liabilities | $8.38M | $8.95M | $6.70M | $4.55M | -6.4% |
| Total debt | $512.00K | $624.00K | $974.00K | $0 | -17.9% |
| Total liabilities | $8.53M | $9.32M | $7.33M | $4.55M | -8.5% |
| Retained earnings | -$154.43M | -$106.45M | -$67.94M | -$32.49M | -45.1% |
| Shareholder equity | $279.70M | $178.95M | $218.97M | $249.82M | +56.3% |
| Working capital | $277.60M | $145.27M | $157.39M | $164.00M | +91.1% |
| Net tangible assets | $279.70M | $178.95M | $218.97M | $249.82M | +56.3% |
| Shares issued | 62.03M | 52.03M | 52.03M | 52.02M | +19.2% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$48.26M | -$38.96M | -$35.59M | -$22.46M | -23.9% |
| Depreciation & amortisation | $335.00K | $315.00K | $315.00K | $47.00K | +6.3% |
| Stock-based compensation | $8.50M | $1.17M | $2.29M | $1.67M | +626.2% |
| Change in working capital | -$3.09M | $188.00K | $1.65M | $2.16M | -1,745.7% |
| Operating cash flow | -$43.55M | -$42.28M | -$33.34M | -$26.20M | -3.0% |
| Capital expenditure | -$121.00K | -$49.00K | -$100.00K | -$67.00K | -146.9% |
| Investing cash flow | $46.17M | $65.14M | -$54.10M | -$84.69M | -29.1% |
| Financing cash flow | $139.65M | -$304.00K | -$204.00K | $0 | +46,037.8% |
| Free cash flow | -$43.67M | -$42.33M | -$33.44M | -$26.27M | -3.2% |
| End cash position | $246.25M | $100.79M | $78.42M | $165.96M | +144.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $12.40M | $12.38M | $11.39M | $10.57M | $8.96M | — | +0.2% |
| Selling, general & admin | $7.06M | $6.37M | $5.25M | $5.92M | $5.75M | — | +10.8% |
| Total operating expense | $19.45M | $18.75M | $16.70M | $16.54M | $14.69M | — | +3.7% |
| Operating income | -$19.45M | -$18.75M | -$16.70M | -$16.54M | -$14.69M | — | -3.7% |
| Net interest income | $966.00K | $582.00K | $722.00K | $980.00K | $1.08M | — | +66.0% |
| Pre-tax income | -$15.15M | -$18.97M | -$14.14M | -$14.02M | -$9.29M | — | +20.1% |
| Tax provision | $0 | $0 | $0 | $0 | $0 | — | — |
| Net income | -$15.15M | -$18.97M | -$14.14M | -$14.02M | -$9.29M | — | +20.1% |
| Net income to common | -$15.15M | -$18.97M | -$14.14M | -$14.02M | -$9.29M | — | +20.1% |
| Basic EPS | -0.23 | -0.31 | — | -0.23 | -0.15 | -0.19 | +25.8% |
| Diluted EPS | -0.23 | -0.31 | — | -0.23 | -0.15 | -0.19 | +25.8% |
| EBIT | -$15.14M | -$18.96M | -$14.13M | -$14.01M | -$9.28M | — | +20.2% |
| EBITDA | -$15.05M | -$18.87M | -$14.04M | -$13.92M | -$9.20M | — | +20.2% |
| Basic shares | 66.53M | 62.03M | — | 62.03M | 62.03M | 58.03M | +7.3% |
| Diluted shares | 66.53M | 62.03M | — | 62.03M | 62.03M | 58.03M | +7.3% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $345.05M | $242.65M | $246.25M | $249.65M | $253.87M | +42.2% |
| Cash & short-term investments | $362.65M | $267.32M | $280.71M | $288.51M | $291.54M | +35.7% |
| Total current assets | $368.82M | $272.23M | $285.98M | $294.79M | $293.88M | +35.5% |
| Property, plant & equipment | $502.00K | $580.00K | $620.00K | $692.00K | $739.00K | -13.4% |
| Total assets | $372.35M | $275.27M | $288.23M | $302.02M | $313.43M | +35.3% |
| Total current liabilities | $12.85M | $11.81M | $8.38M | $10.41M | $9.97M | +8.8% |
| Total debt | $360.00K | $432.00K | $512.00K | $582.00K | $647.00K | -16.7% |
| Total liabilities | $12.86M | $11.89M | $8.53M | $10.63M | $10.25M | +8.1% |
| Retained earnings | -$187.84M | -$173.23M | -$154.43M | -$140.29M | -$126.27M | -8.4% |
| Shareholder equity | $359.49M | $263.38M | $279.70M | $291.40M | $303.18M | +36.5% |
| Working capital | $355.97M | $260.42M | $277.60M | $284.38M | $283.91M | +36.7% |
| Net tangible assets | $359.49M | $263.38M | $279.70M | $291.40M | $303.18M | +36.5% |
| Shares issued | 68.61M | 62.05M | 62.03M | 62.03M | 62.03M | +10.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$15.15M | -$18.97M | -$14.14M | -$14.02M | -$9.29M | +20.1% |
| Depreciation & amortisation | $91.00K | $91.00K | $88.00K | $89.00K | $82.00K | 0.0% |
| Stock-based compensation | $2.16M | $1.83M | $2.66M | $2.33M | $1.88M | +18.0% |
| Change in working capital | -$845.00K | $2.96M | -$1.56M | -$2.90M | $1.16M | -128.5% |
| Operating cash flow | -$15.02M | -$10.67M | -$12.33M | -$13.68M | -$8.97M | -40.8% |
| Capital expenditure | -$17.00K | -$63.00K | -$19.00K | -$39.00K | -$59.00K | +73.0% |
| Investing cash flow | $6.34M | $8.64M | $8.84M | $9.78M | $15.71M | -26.5% |
| Financing cash flow | $111.87M | $2.00K | -$68.00K | -$66.00K | -$1.07M | +5,593,300.0% |
| Free cash flow | -$15.04M | -$10.73M | -$12.35M | -$13.72M | -$9.03M | -40.1% |
| End cash position | $345.05M | $242.65M | $246.25M | $249.65M | $253.87M | +42.2% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
Consensus—
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders—
Held by institutions—
Institutions holding—
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
29.31
-3.33% from price
SMA 20
29.03
-2.40% from price
SMA 50
26.98
+4.99% from price
SMA 100
23.52
+20.44% from price
SMA 200
19.12
+48.18% from price
EMA 12
29.13
-2.74% from price
EMA 26
28.55
-0.78% from price
EMA 50
27.06
+4.70% from price
RSI (14)
49.1
Neutral
MACD (12,26,9)
0.58
Hist -0.24
ATR (14)
1.52
5.37% of price
Realised vol 30D
51.1%
Annualised
Bollinger upper
30.78
20, 2σ
Bollinger lower
27.28
20, 2σ
50 / 200 cross
Golden
26.98 vs 19.12
Trend bias
Above 200
+48.18%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.46
More volatile than market
Correlation to SPY
0.26
Largely independent
Realised vol 30D
51.1%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-27.4%
Peak to trough
Max drawdown 5Y
-81.1%
Peak to trough
ATR 14
1.52
5.37% of price
Beta (reported)
—
5Y monthly, from filing
Headlines
GH Research Reports Second Quarter 2026 Financial Results and Provides Business Update
GlobeNewswire · 17d ago
Is GH Research (GHRS) Trading At A Premium To Fair Value?
Simply Wall St. · 20d ago
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
Stocktwits · 27d ago
Wells Fargo Initiates GH Research at Overweight With $44 Price Target
MT Newswires · 27d ago
Eli Lilly Buys Psychedelics Maker Atai Beckley for $2.8 Billion to Develop DMT-Like Depression Drug
24/7 Wall St. · 37d ago
Why Psychedelic stocks are surging today
Investing.com · 38d ago
GH Research gains on optimism surrounding potential Eli Lilly-Atai deal (GHRS)
InvestorsHub · 38d ago
The Race to Commercialize the World’s Most Powerful Psychedelic
WSJ · 39d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.